Frank W. Lee
About
Frank W. Lee is a scholar working on Pharmacology, Oncology and Infectious Diseases.
According to data from OpenAlex, Frank W. Lee has authored 21 papers receiving a total of 698 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 7 papers in Oncology and 3 papers in Infectious Diseases. Recurrent topics in Frank W. Lee's work include Pharmacogenetics and Drug Metabolism (9 papers), Drug Transport and Resistance Mechanisms (7 papers) and Computational Drug Discovery Methods (3 papers). Frank W. Lee is often cited by papers focused on Pharmacogenetics and Drug Metabolism (9 papers), Drug Transport and Resistance Mechanisms (7 papers) and Computational Drug Discovery Methods (3 papers). Frank W. Lee collaborates with scholars based in United States, Netherlands and Germany. Frank W. Lee's co-authors include Suresh K. Balani, Liang‐Shang Gan, Jing‐Tao Wu, Gerald T. Miwa, H. Neal Bramson, Eric Solon, Kenneth W. Batchelor, Stephen V. Frye, David Hermann and Michael K. James and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Biochemical Pharmacology and Drug Metabolism and Disposition.
In The Last Decade
Frank W. Lee
21 papers receiving 666 citations
Peers
Frank W. Lee
Rikard Sandström Sweden
Kumiko Noda Japan
M Zschiesche Germany
Osamu Sugita Japan
Yasuro KAWAGUCHI Japan
Thomas Wendl Germany
H. Noguchi Japan
Hitoshi Ishizuka Japan
Justin D. Lutz United States
Renée Portmann Switzerland
Citations per year, relative to Frank W. Lee Frank W. Lee (= 1×)
peers
Rikard Sandström
Countries citing papers authored by Frank W. Lee
Since
Specialization
Citations
This map shows the geographic impact of Frank W. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank W. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank W. Lee more than expected).
Fields of papers citing papers by Frank W. Lee
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Frank W. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank W. Lee. The network helps show where Frank W. Lee may publish in the future.
Co-authorship network of co-authors of Frank W. Lee
This figure shows the co-authorship network connecting the top 25 collaborators of Frank W. Lee. A scholar is included among the top collaborators of Frank W. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank W. Lee. Frank W. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yang, Johnny, Mark Milton, Shaoxia Yu, et al.. (2010). P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor. Drug Metabolism Letters. 4(4). 202–212.
2.
Liao, Mingxiang, Michael Chen, Qing Zhu, et al.. (2010). Inhibition of Hepatic Organic Anion-Transporting Polypeptide by RNA Interference in Sandwich-Cultured Human Hepatocytes: An In Vitro Model to Assess Transporter-Mediated Drug-Drug Interactions. Drug Metabolism and Disposition. 38(9). 1612–1622.
3.
Garner, C. Edwin, Eric Solon, Chii‐Ming Lai, et al.. (2008). Role of P-Glycoprotein and the Intestine in the Excretion of DPC 333 [(2R)-2-{(3R)-3-Amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide] in Rodents. Drug Metabolism and Disposition. 36(6). 1102–1110.
4.
Lu, Chuang, et al.. (2008). Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. III. In Vitro-in Vivo Correlation with Fluconazole. Drug Metabolism and Disposition. 36(7). 1261–1266.
5.
Balani, Suresh K., et al.. (2008). Proposed New Addition to 3Rs for Ethical and Humane Use of Rats in Pharmacokinetic Studies – ‘Recycle’. Drug Metabolism Letters. 2(3). 193–197.
6.
Lu, Chuang, et al.. (2008). Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. II. In Vitro-in Vivo Correlation with Ketoconazole. Drug Metabolism and Disposition. 36(7). 1255–1260.
7.
Luo, Gang, C. Edwin Garner, Hao Xiong, et al.. (2007). Effect of DPC 333 [(2R)-2-{(3R)-3-Amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a Human Tumor Necrosis Factor α-Converting Enzyme Inhibitor, on the Disposition of Methotrexate: A Transporter-Based Drug-Drug Interaction Case Study. Drug Metabolism and Disposition. 35(6). 835–840.
8.
Frye, Stephen V., H. Neal Bramson, David Hermann, et al.. (2006). Discovery and Development of GG745, a Potent Inhibitor of Both Isozymes of of 5α-Reductase. Kluwer Academic Publishers eBooks. 11. 393–422.
9.
Blanchard, Steven G., Robert Andrews, Peter J. Brown, et al.. (2006). Discovery of Bioavailable Inhibitors of Secretory Phospholipase A2. Kluwer Academic Publishers eBooks. 11. 445–463.
10.
Balani, Suresh K., N. Nagaraja, Mark G. Qian, et al.. (2005). EVALUATION OF MICRODOSING TO ASSESS PHARMACOKINETIC LINEARITY IN RATS USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY. Drug Metabolism and Disposition. 34(3). 384–388.
11.
Balani, Suresh K., Gerald T. Miwa, Liang‐Shang Gan, Jing‐Tao Wu, & Frank W. Lee. (2005). Strategy of Utilizing In Vitro and In Vivo ADME Tools for Lead Optimization and Drug Candidate Selection. Current Topics in Medicinal Chemistry. 5(11). 1033–1038.
12.
Balani, Suresh K., Ping Li, Joanne Nguyen, et al.. (2004). EFFECTIVE DOSING REGIMEN OF 1-AMINOBENZOTRIAZOLE FOR INHIBITION OF ANTIPYRINE CLEARANCE IN GUINEA PIGS AND MICE USING SERIAL SAMPLING. Drug Metabolism and Disposition. 32(10). 1092–1095.
13.
Luo, Gang, Lin Jian-rong, William D. Fiske, et al.. (2003). CONCURRENT INDUCTION AND MECHANISM-BASED INACTIVATION OF CYP3A4 BY AN l-VALINAMIDE DERIVATIVE. Drug Metabolism and Disposition. 31(9). 1170–1175.
14.
Balani, Suresh K., Tong Zhu, Tian J. Yang, et al.. (2002). Effective Dosing Regimen of 1-Aminobenzotriazole for Inhibition of Antipyrine Clearance in Rats, Dogs, and Monkeys. Drug Metabolism and Disposition. 30(10). 1059–1062.
15.
Solon, Eric, Suresh K. Balani, Gang Luo, et al.. (2002). Interaction of Ritonavir on Tissue Distribution of a [14C]L-Valinamide, a Potent Human Immunodeficiency Virus-1 Protease Inhibitor, in Rats Using Quantitative Whole-Body Autoradiography. Drug Metabolism and Disposition. 30(11). 1164–1169.
16.
Solon, Eric, Suresh K. Balani, & Frank W. Lee. (2002). Whole-Body Autoradiography In Drug Discovery. Current Drug Metabolism. 3(5). 451–462.
17.
Stuart, J. Darren, Frank W. Lee, Sue H. Kadwell, et al.. (2001). Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5α-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat 3 3Abbreviations: r5AR1, rat 5α-reductase 1; r5AR2, rat 5α-reductase 2; and DHT, dihydrotestosterone.. Biochemical Pharmacology. 62(7). 933–942.
18.
Lee, Frank W., Tomas Salmonson, & Leslie Z. Benet. (1993). Pharmacokinetics and pharmacodynamics of nitroglycerin and its dinitrate metabolites in conscious dogs: Intravenous infusion studies. Journal of Pharmacokinetics and Biopharmaceutics. 21(5). 533–550.
19.
Lee, Frank W., et al.. (1993). Nitroglycerin dinitrate metabolites do not affect the pharmacokinetics and pharmacodynamics of nitroglycerin in the dog: A preliminary report. Journal of Pharmacokinetics and Biopharmaceutics. 21(2). 163–173.
20.
Lee, Frank W., et al.. (1988). Simultaneous determination of nitroglycerin and its dinitrate metabolites by capillary gas chromatography with electron-capture detection. Journal of Chromatography B Biomedical Sciences and Applications. 426(2). 259–266.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Rikard Sandström Breakdown of academic impact, for papers by Kumiko Noda Breakdown of academic impact, for papers by M Zschiesche Breakdown of academic impact, for papers by Osamu Sugita Breakdown of academic impact, for papers by Yasuro KAWAGUCHI Breakdown of academic impact, for papers by Thomas Wendl Breakdown of academic impact, for papers by H. Noguchi Breakdown of academic impact, for papers by Hitoshi Ishizuka Breakdown of academic impact, for papers by Justin D. Lutz Breakdown of academic impact, for papers by Renée Portmann